Drug Offers 'Stunning' Improvement in Dry AMD |
Journal Updates
eMediNexus Coverage from: 
Drug Offers 'Stunning' Improvement in Dry AMD

0 Read Comments                

Patients with non-exudative (dry) age-related macular degeneration (dAMD) obtained meaningful vision improvement at 6 months with a drug targeting oxidative stress versus sham treatment in a phase II clinical trial.

Results showed that 12 of 25 patients improved by ≥8 ETDRS letters in best corrected visual acuity (BCVA) at 28 weeks with risuteganib as compared with one of 14 patients in the sham group. The drug was well tolerated, David S. Boyer, MD, of Retina-Vitreous Associates Medical Group in Los Angeles, reported at the American Academy of Ophthalmology meeting.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now